The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

The combination of lasofoxifene and abemaciclib provided a meaningful progression-free survival benefit and elicited encouraging responses with an acceptable toxicity profile in patients with locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer.

Extended follow-up data from the LIBRETTO-001 demonstrated that selpercatinib elicited durable responses in patients with RET fusion-positive solid tumors, including refractory gastrointestinal malignancies.

Treatment with pacritinib demonstrated a comparable safety profile to best available therapies for the treatment of patients with myelofibrosis.

Ibrutinib in combination with bendamustine and rituximab with rituximab maintenance elicited a significant improvement in progression-free survival compared with standard chemoimmunotherapy in older patients with mantle cell lymphoma.

Jaffer A. Ajani, MD, discusses how the FDA approvals of first-line nivolumab plus chemotherapy and nivolumab plus ipilimumab in advanced or metastatic esophageal squamous cell carcinoma will improve treatment in this setting.

For the 10th consecutive year, OncLive® is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Ishwaria M. Subbiah, MD, MS, brings attention to the perpetrators of sexual harassment, outlines the nuances of how these experiences affect personal wellbeing and job satisfaction, and highlights the need for accountability as a first step toward systemic change across the oncology community.

The safety and efficacy of encorafenib plus cetuximab with or without standard-of-care chemotherapy will be compared with that of chemotherapy alone in patients with BRAF V600E–mutated metastatic colorectal cancer as part of the phase 3 BREAKWATER trial.

Nadofaragene firadenovec combined with immune checkpoint inhibitors such as pembrolizumab may play a synergistic role in the treatment of patients with Bacillus Calmette–Guérin-unresponsive non–muscle invasive bladder cancer.

Anirban P. Mitra, MD, PhD, discusses data from an assessment of PD-1 and PD-L1 status on transurethral resection specimens collected from patients with non–muscle-invasive bladder cancer who received nadofaragene firadenovec as part of a phase 3 trial.

The addition of navicixizumab to paclitaxel produced encouraging responses with manageable toxicity in patients with platinum-resistant ovarian cancer irrespective of prior treatment with bevacizumab.

Seventy percent of practicing oncologists had experienced sexual harassment by peers or superiors within 1 year, highlighting a substantial issue for both women and men, according to findings from a study that were published in the Journal of Clinical Oncology.

Up to 40% of patients with diffuse large B-cell lymphoma are refractory to or relapse after first-line treatment.

Srdan Verstovsek, MD, PhD, discusses the future of ALK2 inhibitors in myelofibrosis.

Jason R. Westin, MD, discusses the evolving landscape of CAR T-cell therapy in non-Hodgkin lymphoma.

Srdan Verstovsek, MD, PhD, discusses addressing anemia in patients with myelofibrosis.

The University of Texas MD Anderson Cancer Center was awarded more than $10 million in grants to support collaborative research teams working to advance novel interception and treatment strategies that will improve outcomes for several cancer types with the greatest unmet need.

Srdan Verstovsek, MD, PhD, discusses the preliminary results of the MOMENTUM study and the potential for ALK2 inhibitor success in the larger anemia treatment landscape.

Srdan Verstovsek, MD, PhD, discusses the mechanisms of action of momelotinib in myelofibrosis.

Yi Lin, MD, PhD, discusses treatment updates in CAR T-cell therapy in multiple myeloma.

The addition of novel anti–LAG-3 antibody relatlimab-rmbw to antiPD-1 antibody nivolumab offers treatment-naïve patients with unresectable or metastatic melanoma an efficacious and tolerable immunotherapy treatment option.

Hussein A. Tawbi, MD, PhD, discusses the utilization of relatlimab plus nivolumab in unresectable or metastatic melanoma.

David S. Hong, MD, discusses data examining the use of sotorasib (Lumakras) and adagrasib in colorectal cancer.

Tapan M. Kadia, MD, discusses what makes uproleselan unique from other agents under investigation in acute myeloid leukemia and sheds light on the many research efforts dedicated to further exploring its use in this disease.

The combination of the CD40 agonist antibody sotigalimab and pembrolizumab demonstrated a favorable safety profile and led to immunologic changes that correlated with clinical response in patients with unresectable stage III or IV metastatic melanoma.

Scott Kopetz, MD, PhD, FACP, discusses the phase 3 BEACON CRC study and the subsequent efficacy response analysis in patients with BRAF V600E–mutant metastatic colorectal cancer.

The investigational Wee1 inhibitor ZN-c3 was found to be safe and to produce a disease control rate of 90.9% and an objective response rate of 27.3% in patients with advanced or recurrent uterine serous carcinoma.

Durvalumab plus either oleclumab, monalizumab, or damvatirsen led to an improvement in major pathologic response vs durvalumab alone as neoadjuvant therapy in patients with resectable, early-stage non–small cell lung cancer, according to findings from the phase 2 NeoCOAST clinical trial.

The oral ataxia-telangiectasia and Rad3–related protein inhibitor elimusertib produced durable and prolonged responses in patients with advanced solid tumors who have ATM gene alterations and BRCA1/2 defects.

The T-cell attributes of axicabtagene ciloleucel impacted tumor burden, efficacy outcomes, peak levels of proinflammatory cytokines, and toxicities such as neurologic events and cytokine release syndrome in patients with relapsed/refractory large B-cell lymphoma.